Wetenschap

Hieronder vindt u een opsomming van reeds gepubliceerde artikelen met een link naar het betreffende artikel. Een aantal artikelen worden binnenkort naar verwachting geaccepteerd en wordt aan de lijst toegevoegd.
 

1. Van Erp LW, Thomas PW, Groenen MJ, Bloem S, Russel MG, Römkens TE, Wahab PJ. External Validity and Consistency over Time of Patient Segmentation Based on Disease Acceptance and Perceived Control in Inflammatory Bowel Disease. J Gastrointestin Liver Dis. 2023 Sep 28;32(3):306-314. doi: 10.15403/jgld-4855. PMID: 37774220.

2. Thomas PWA, van Caem M, West RL, Russel MGVM, Jansen JM, Römkens TEH, Hoentjen F; IBDREAM registry. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study. Eur J Gastroenterol Hepatol. 2023 Mar 1;35(3):261-269.
   Doi: 10.1097/MEG.0000000000002506. PMID: 36708296

3. Thomas PWA, den Broeder N, Derikx M, Kievit W, West RL, Russel MGVM, Jansen JM, Römkens TEH, Hoentjen F. Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study. Inflamm Bowel Dis. 2022 Dec 1;28(12):1813-1820.
   Doi: 10.1093/ibd/izac002. PMID: 35134917

4. Thomas PWA, Römkens TEH, West RL, Russel MGVM, Jansen JM, van Lint JA, Jessurun NT, Hoentjen F. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy. United European Gastroenterol J. 2021 Oct;9(8):919-928.
   Doi: 10.1002/ueg2.12107. PMID: 34077634

5. Thomas PWA, Smits LJT, Te Groen M, West RL, Russel MGVM, Jansen JM, Römkens TEH, Hoentjen F; IBDREAM. De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation. Eur J Gastroenterol Hepatol. 2022 May 1;34(5):488-495.
   Doi: 10.1097/MEG.0000000000002336. PMID: 34974465

6. Thomas PWA, West RL, Russel MGVM, Jansen JM, Kosse LJ, Jessurun NT, Römkens TEH, Hoentjen F; IBDREAM registry. Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system. Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):520-524.
   Doi: 10.1002/pds.5175. PMID: 33219593

7. Giraud EL, Thomas PWA, van Lint JA, van Puijenbroek EP, Römkens TEH, West RL, Russel MGVM, Jansen JM, Jessurun NT, Hoentjen F; IBDREAM registry. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. Drug Saf. 2021 May;44(5):581-588.
   Doi: 10.1007/s40264-021-01045-3. PMID: 33538994

8. de Jong ME, Taal E, Thomas PWA, Römkens TEH, Jansen JM, West RL, Slotman E, Hoentjen F, Russel MGVM. Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease. Scand J Gastroenterol. 2021 Feb;56(2):155-161.
   Doi: 10.1080/00365521.2020.1857430. PMID: 33300822.

9. de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel MGVM, Römkens TEH, West RL, Jansen JM, Hoentjen F. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients. J Crohns Colitis. 2020 Jul 30;14(7):888-895.
   Doi: 10.1093/ecco-jcc/jjaa012. PMID: 31974546.

10. Broekharst DSE, Thomas PWA, Russel MGVM, West RL, Jansen JM, Bloem S, Römkens TEH. Health State Questionnaires Deployed in Ulcerative Colitis Patients: The Medical, Psychological, and Economic Perspective. Gastro Hep Adv. 2023 Mar 18;2(6):770-777. doi: 10.1016/j.gastha.2023.03.020.